Senate Bill 215

By: Senator Tarver of the 22nd

A BILL TO BE ENTITLED AN ACT

- 1 To amend Title 33 of the Official Code of Georgia Annotated, relating to insurance, so as to
- 2 provide for an independent review of certain health insurance decisions; to provide for
- 3 definitions; to provide for review criteria; to provide for limitations; to provide for
- 4 procedures; to provide for requirements of an independent review organization; to provide
- 5 for related matters; to repeal conflicting laws; and for other purposes.

6 BE IT ENACTED BY THE GENERAL ASSEMBLY OF GEORGIA:

7 SECTION 1.

- 8 Title 33 of the Official Code of Georgia Annotated, relating to insurance, is amended by
- 9 adding a new chapter to read as follows:

10 "CHAPTER 20C

- 11 <u>33-20C-1</u>.
- 12 As used in this chapter, the term:
- 13 (1) 'Department' means the Department of Community Health established under Chapter
- 14 <u>5A of Title 31.</u>
- 15 (2) 'Enrollee' means the individual who has elected to contract for or participate in a
- health benefit plan for himself or herself or both himself or herself and his or her eligible
- dependents.
- 18 (3) 'Health benefit plan' means a plan of benefits that defines the coverage provisions for
- health care for enrollees offered or provided by any organization, public or private.
- 20 (4) 'Health care provider' means any person, corporation, facility, or institution licensed
- by this state or any other state to provide or otherwise lawfully providing health care
- services, including, but not limited to, a doctor of medicine, doctor of osteopathy, hospital
- or other health care facility, dentist, nurse, optometrist, podiatrist, physical therapist,

psychologist, occupational therapist, professional counselor, pharmacist, chiropractor,

24

25 marriage and family therapist, or social worker. (5) 'Independent review organization' means any organization certified as such by the 26 27 department under Code Section 33-20A-39. 28 (6) 'Medical and scientific evidence' means: 29 (A) Peer reviewed scientific studies published in or accepted for publication by 30 medical journals that meet nationally recognized requirements for scientific 31 manuscripts and that submit most of their published articles for review by experts who 32 are not part of the editorial staff; 33 (B) Peer reviewed literature, biomedical compendia, and other medical literature that 34 meet the criteria of the National Institutes of Health's National Library of Medicine for 35 indexing in *Index Medicus* or Excerpta Medica (EMBASE), MEDLINE, MEDLARS, 36 or Health Services Technology Assessment Research (HSTAR) data bases; 37 (C) Medical journals recognized by the United States secretary of health and human 38 services, under Section 1861(t)(2) of the Social Security Act; 39 (D) The following standard reference compendia: the American Hospital Formulary 40 Service-Drug Information, the American Medical Association Drug Evaluation, the 41 American Dental Association Accepted Dental Therapeutics, and the United States 42 Pharmacopoeia-Drug Information; or (E) Findings, studies, or research conducted by or under the auspices of federal 43 44 government agencies and nationally recognized federal research institutes, including the Federal Agency for Health Care Policy and Research, National Institutes of Health, 45 National Cancer Institute, National Academy of Sciences, the Centers for Medicare and 46 47 Medicaid Services, and any national board recognized by the National Institutes of 48 Health for the purpose of evaluating the medical value of health services. 49 (7) 'Payor' means any insurer, as defined in this title, or any preferred provider 50 organization, health maintenance organization, self-insurance plan, or other person or 51 entity which provides, offers to provide, or administers hospital, outpatient, medical, or other health care benefits to persons treated by a health care provider in this state 52 53 pursuant to any policy, plan, or contract of accident and sickness insurance as defined in 54 Code Section 33-7-2. 55 (8) 'Treatment' means a medical service, diagnosis, procedure, therapy, drug, or device. 56 33-20C-2. 57 An enrollee shall be entitled to appeal to an independent review organization when: (1) The enrollee has received notice of denial for a covered service or therapy or any 58 59 limitation of such covered service or therapy; or

(2) A payor determines that a proposed treatment is excluded as experimental under the

60

61 health benefit plan, and all of the following criteria are met: 62 (A) The enrollee has a terminal condition that, according to the treating physician, has 63 a substantial probability of causing death within two years from the date of the request 64 for independent review or the enrollee's ability to regain or maintain maximum 65 function, as determined by the treating physician, would be impaired by withholding 66 such experimental treatment; 67 (B) After exhaustion of standard treatment as provided by the evidence of coverage or 68 a finding that such treatment would be of substantially lesser or of no benefit, the 69 enrollee's treating physician certifies that the enrollee has a condition for which 70 standard treatment would not be medically indicated for the enrollee or for which there 71 is no standard treatment available under the evidence of coverage of the enrollee more 72 beneficial than the treatment proposed; 73 (C) The enrollee's treating physician has recommended and certified in writing 74 treatment which is likely to be more beneficial to the enrollee than any available 75 standard treatment; 76 (D) The enrollee has requested a treatment as to which the enrollee's treating physician, 77 who is a licensed, board certified, or board eligible physician qualified to practice in the 78 area of medicine appropriate to treat the enrollee's condition, has certified in writing 79 that scientifically valid studies using accepted protocols, such as control group or 80 double-blind testing, published in peer reviewed literature, demonstrate that the 81 proposed treatment is likely to be more beneficial for the enrollee than available 82 standard treatment; and 83 (E) A specific treatment recommended would otherwise be included within the 84 enrollee's certificate of coverage, except for the determination by the payor that such 85 treatment is experimental for a particular condition. 86 33-20C-3. 87 Except where required pursuant to Code Section 51-1-49, a proposed treatment shall require the expenditure of a minimum of \$500.00 to qualify for independent review. 88 89 33-20C-4. (a) The parent or guardian of a minor who is an enrollee may act on behalf of such minor 90 91 in requesting independent review. The legal guardian or representative of an incapacitated 92 enrollee shall be authorized to act on behalf of such enrollee in requesting independent 93 review. Except as provided in Code Section 51-1-49, independent review shall not be

94 requested by persons other than the enrollee or a person acting on behalf of the enrollee as

- 95 provided in this Code section.
- 96 (b) A payor shall be required to pay the full cost of applying for and obtaining the
- 97 independent review.
- 98 (c) The enrollee and the payor shall cooperate with the independent review organization
- 99 to provide the information and documentation, including executing necessary releases for
- medical records, which are necessary for the independent review organization to make a
- determination of the claim.
- 102 <u>33-20C-5.</u>
- (a) The payor shall include with the written notice of denial of service a statement
- specifying that any request for independent review must be made to the department on
- forms developed by the department, and such forms shall be included with the notification.
- Such statement shall be in simple, clear language in boldface type which is larger and
- bolder than any other typeface which is in the notice and in at least 14 point typeface.
- 108 (b) An enrollee shall submit the written request for independent review to the department.
- 109 <u>Instructions on how to request independent review shall be given to all enrollees with the</u>
- written notice required under this Code section together with instructions in simple, clear
- language as to what information, documentation, and procedures are required for
- independent review.
- (c) Upon receipt of a completed form requesting independent review as required by
- subsection (a) of this Code section, the department shall notify the enrollee of receipt and
- assign the request to an independent review organization on a rotating basis according to
- the date the request is received.
- 117 (d) Upon assigning a request for independent review to an independent review
- organization, the department shall provide written notification of the name and address of
- the assigned independent review organization to both the requesting enrollee and the payor.
- (e) No payor shall be licensed by the Commissioner of Insurance under this title unless the
- payor agrees to pay the costs of independent review to the independent review organization
- assigned by the department to conduct each review involving such payor's enrollees.
- 123 33-20C-6.
- (a) Within three business days of receipt of notice from the department of assignment of
- the application for determination to an independent review organization, the payor shall
- submit to that independent review organization:
- (1) Any information submitted to the payor by the enrollee in support of the enrollee's
- 128 <u>claim;</u>

(2) A copy of the contract provisions or evidence of coverage of the health benefit plan; 129 130 and 131 (3) Any other relevant documents or information used by the payor in determining the 132 outcome of the enrollee's denied claim. 133 Upon request, the payor shall provide a copy of all documents required by this subsection, 134 except for any proprietary or privileged information, to the enrollee. The enrollee may 135 provide the independent review organization with any additional information the enrollee 136 deems relevant. (b) The independent review organization shall request any additional information required 137 for the review from the payor and the enrollee within five business days of receipt of the 138 139 documentation required under this Code section. Any additional information requested by 140 the independent review organization shall be submitted within five business days of receipt 141 of the request, or an explanation of why the additional information is not being submitted 142 shall be provided. (c) Additional information obtained from the enrollee shall be transmitted to the payor, 143 144 which may determine that such additional information justifies a reconsideration of the 145 outcome of the denial. A decision by the payor to cover fully the treatment in question 146 upon reconsideration using such additional information shall terminate the independent 147 review. 148 (d) The expert reviewer of the independent review organization shall make a determination 149 within 15 business days after expiration of all time limits set forth in this Code section, but 150 such time limits may be extended or shortened by mutual agreement between the enrollee and the payor. The determination shall be in writing and shall state the basis of the 151 152 reviewer's decision. A copy of the decision shall be delivered to the payor, the enrollee, 153 and the department by at least first-class mail. (e) The independent review organization's decision shall be based upon a review of the 154 155 information and documentation submitted to it. (f) Information required or authorized to be provided pursuant to this Code section may 156 157 be provided by facsimile transmission or other electronic transmission. 158 33-20C-7. (a) A decision of the independent review organization in favor of the enrollee shall be final 159 160 and binding on the payor, and the appropriate relief shall be provided without delay. A payor bound by such decision of an independent review organization shall not be liable 161 pursuant to Code Section 51-1-48 for abiding by such decision. Nothing in this Code 162 section shall relieve the payor from liability for damages proximately caused by its 163 164 determination of the proposed treatment prior to such decision.

165 (b) A determination by the independent review organization in favor of a payor shall create a rebuttable presumption in any subsequent action that the payor's prior determination was 166 167 appropriate and shall constitute a medical record for purposes of Code Section 24-7-8. 168 (c) In the event that, in the judgment of the treating health care provider, the health 169 condition of the enrollee is such that following the provisions of Code Section 33-20C-6 170 would jeopardize the life or health of the enrollee or the enrollee's ability to regain 171 maximum function, as determined by the treating health care provider, an expedited review 172 shall be available. The expedited review process shall encompass all elements enumerated 173 in Code Sections 33-20C-6, 33-20C-10, and 33-20C-11; provided, however, that a decision 174 by the expert reviewer shall be rendered within 72 hours after the expert reviewer's receipt 175 of all available requested documents. 176 33-20C-8. 177 Neither an independent review organization nor its employees, agents, or contractors shall 178 be liable for damages arising from determinations made pursuant to this chapter, unless an 179 act or omission thereof is made in bad faith or through gross negligence, constitutes fraud 180 or willful misconduct, or demonstrates malice, wantonness, oppression, or that entire want 181 of care which would raise the presumption of conscious indifference to the consequences. 182 33-20C-9. (a) The department shall certify independent review organizations that meet the 183 requirements of this Code section and any regulations promulgated by the department 184 consistent with this chapter. The department shall deem certified any independent review 185 organization meeting standards developed for this purpose by an independent national 186 187 accrediting organization. To qualify for certification, an independent review organization shall be subject to the following conditions: 188 189 (1) Expert reviewers assigned by the independent review organization shall be physicians 190 or other appropriate health care providers who meet the following minimum 191 requirements: 192 (A) Are expert in the treatment of the medical condition at issue and are 193 knowledgeable about the recommended treatment through actual clinical experience; 194 (B) Hold a nonrestricted license issued by a state of the United States and, for 195 physicians, a current certification by a recognized American medical specialty board in the area or areas appropriate to the subject of review; and 196 197 (C) Have no history of disciplinary action or sanctions, including, but not limited to, 198 loss of staff privileges or participation restriction, taken or pending by any hospital, 199 government, or regulatory body;

200	(2) The independent review organization shall not be a subsidiary of, nor in any way
201	owned or controlled by, a health plan, a trade association of health plans, a managed care
202	entity, or a professional association of health care providers; and
203	(3) The independent review organization shall submit to the department the following
204	information upon initial application for certification, and thereafter within 30 days of any
205	change to any of the following information:
206	(A) The names of all owners of more than 5 percent of any stock or options, if a
207	publicly held organization;
208	(B) The names of all holders of bonds or notes in excess of \$100,000.00, if any;
209	(C) The names of all corporations and organizations that the independent review
210	organization controls or is affiliated with, and the nature and extent of any ownership
211	or control, including the affiliated organization's type of business; and
212	(D) The names of all directors, officers, and executives of the independent review
213	organization, as well as a statement regarding any relationships the directors, officers,
214	and executives may have with any health care service plan, disability insurer, managed
215	care entity or organization, health care provider group, or board or committee.
216	(b) Neither the independent review organization nor any expert reviewer of the
217	independent review organization shall have any material professional, familial, or financial
218	conflict of interest with any of the following:
219	(1) A health benefit plan or payor being reviewed;
220	(2) Any officer, director, or management employee of a health benefit plan which is
221	being reviewed;
222	(3) The physician, the physician's medical group, health care provider, or the
223	independent practice association proposing a treatment under review;
224	(4) The institution at which a proposed treatment would be provided;
225	(5) The enrollee or the enrollee's representative; or
226	(6) The development or manufacture of the treatment proposed for the enrollee whose
227	treatment is under review.
228	(c) As used in subsection (b) of this Code section, the term 'conflict of interest' shall not
229	be interpreted to include a contract under which an academic medical center or other
230	similar medical research center provides health care services to enrollees of a health benefit
231	plan, except as subject to the requirement of paragraph (4) of subsection (b) of this Code
232	section; affiliations which are limited to staff privileges at a health care facility; or an
233	expert reviewer's participation as a contracting plan provider where the expert is affiliated
234	with an academic medical center or other similar medical research center that is acting as
235	an independent review organization under this chapter. An agreement to provide

independent review for an enrollee or payor shall not be a conflict of interest under subsection (b) of this Code section.
 (d) The independent review organization shall have a quality assurance mechanism in place that ensures the timeliness and quality of the reviews, the qualifications and

- independence of the experts, and the confidentiality of medical records and review
- 241 materials.

240

- (e) The department shall provide upon the request of any interested person a copy of all
- 243 <u>nonproprietary information filed with it pursuant to this chapter.</u> The department shall
- provide at least quarterly a current list of certified independent review organizations to all
- health benefit plan entities and to any interested persons.
- 246 33-20C-10.
- 247 For the purposes of this chapter, in making a determination as to whether a covered service
- 248 and any limitation for such covered service is medically necessary and appropriate, the
- 249 expert reviewer shall, in addition to the factors provided in Code Section 33-20C-11,
- 250 consider whether such services or therapies are clinically appropriate, including, but not
- 251 <u>limited to, in terms of type, frequency, extent, site, duration, and effectiveness for the</u>
- 252 patient's illness, injury, or disease.
- 253 33-20C-11.
- 254 (a) For the purposes of this chapter, in making a determination as to whether a treatment
- is medically necessary and appropriate, the expert reviewer shall determine, based upon
- 256 generally accepted medical practices in light of conditions at the time of such treatment,
- 257 <u>whether such treatment is:</u>
- 258 (1) Appropriate and consistent with the diagnosis and the omission of which could
- adversely affect or fail to improve the enrollee's condition;
- 260 (2) Compatible with the standards of acceptable medical practice in the United States;
- 261 (3) Provided in a safe and appropriate setting given the nature of the diagnosis and the
- severity of the symptoms;
- 263 (4) Not provided solely for the convenience of the enrollee or the convenience of the
- health care provider or hospital; and
- 265 (5) Not primarily custodial care, unless custodial care is a covered service or benefit
- under the enrollee's evidence of coverage.
- 267 (b) For the purposes of this chapter, in making a determination as to whether a treatment
- is experimental, the expert reviewer shall determine:
- 269 (1) Whether such treatment has been approved by the federal Food and Drug
- Administration; or

271	(2) Whether medical and scientific evidence demonstrates that the expected benefits of
272	the proposed treatment would be greater than the benefits of any available standard
273	treatment and that the adverse risks of the proposed treatment will not be substantially
274	increased over those of standard treatments.
275	For either determination, the expert reviewer shall apply prudent professional practices and
276	shall assure that at least two documents of medical and scientific evidence support the
277	decision.
278	33-20C-12.
279	The department shall provide necessary rules and regulations for the implementation and
280	operation of this chapter."
281	SECTION 2.
282	All laws and parts of laws in conflict with this Act are repealed.